NASDAQ:APLS 30 October 2025 - 12 January 2026

Apellis Pharmaceuticals shares climbed nearly 8% to $25.85 midday Wednesday as investors positioned ahead of the company’s Jan. 12 presentation at the J.P. Morgan Healthcare Conference. Traders are watching for updates on Syfovre and Empaveli, with recent SEC filings and competitive pressures drawing attention to the stock’s moves.

Apellis Pharmaceuticals reported Q3 2025 revenue of $458.6 million and a $215.7 million net profit, but its stock fell about 21% after management warned of future losses. Syfovre sales in the U.S. were flat at $150.9 million, with modest injection growth and ongoing debate over its benefits. Empaveli gained FDA approval for rare kidney diseases in July. Analyst ratings and price targets remain divided.